Chemotherapy for soft tissue sarcomas. Indications and advances

Acta Orthopaedica Scandinavica, Supplement

Volumn 68, Issue 273, 1997, Pages 133-138

  Phillips, Kelly Anne ^a   Toner, Guy C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; IFOSFAMIDE; METHOTREXATE; TOPOTECAN; VINCRISTINE; CYVADIC PROTOCOL;

CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; HUMAN; LIVER METASTASIS; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; ADJUVANT CHEMOTHERAPY; ADULT; DOSE RESPONSE; METASTASIS; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; SARCOMA; SOFT TISSUE TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; NEOPLASM METASTASIS; PREOPERATIVE CARE; SARCOMA; SOFT TISSUE NEOPLASMS; VINCRISTINE;

EID: 0031066111     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Alvegard T A, Sigurdsson H, Mouridsen H, et al. (1989). Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomised trial of the Scandinavian Sarcoma Group. J Clin Oncol 7: 1504-13.
2. Antman K H, Elias A D (1988). Chemotherapy of advanced soft tissue sarcomas. Sem Surg Oncol 4: 53-58.
3. Antman K H, Ryan L, Elias A, et al. (1989). Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131.
4. Antman K, Ryan L, Borden E, et al. (1990). Pooled results from three randomised adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature. In: Adjuvant Therapy of Cancer VI. (Ed. Salmon S E). W.B. Saunders Co. Philadelphia, pp 529-43.
5. Benjamin R S, Gottlieb J A, Baker L H, et al. (1978). CYVADIC vs CYVADACT- a randomised trial of cyclophosphamide (CY), vincristine (V), and Adriamycin (A) plus either dacarbazine (DIC ) or actinomycin-D(DACT) on metastatic sarcomas. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 17: 256.
6. Benjamin T, Terjanian T , Fenoglio C J et al. (1987). The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In: Adjuvant Therapy of Cancer (Ed. Salmon S E). Grune and Stratton Orlando, pp 735-44.
7. Borden E C, Amato D, Enterline H T, et al. (1987). Randomised comparison of Adriamycin regimens for treatment of metastatic soft tissue sarcomas. J Clin Oncol 5: 840-50.
8. Bramwell V H, Eisenhauer E A, Blackstein, M, et al. (1995). Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6: 847-49.
9. Bramwell V, Mouridsen H, Santoro G, et al. (1987). Cyclophosphamide vs ifosfamide: Final report of a randomised phase II trial in adult soft tissue sarcoma. Eur J Cancer 23: 311-21.
10. Bramwell V, Rouesse J, Steward W, et al. (1994). Adjuvant CYVADIC chemotherapy for adult soft tissue sarcomareduced local recurrence but no improvement in survival: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 12: 1137-49.
11. Casper E S, Christman K L, Schwanz G K, et al. (1993). Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma. Cancer 72: 766-70.
12. Chang A E, Kinsella T, Glatstein E, et al. (1988). Adjuvant chemotherapy for patients with high grade soft tissue sarcomas of the extremity. J Clin Oncol 6: 1491-1500.
13. Chevallier B, Montcuquet P, Fachini T, et al. (1990). Phase II study of epirubicin in advanced soft tissue sarcoma. Bull Cancer 77: 991-95.
14. Demetri G D, Elias A D (1995). Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin (Nth Am) 9 (4): 765-85.
15. Edmonson J H, Fleming T R, Ivins J C et al. (1984). Randomised study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol 2: 1390-96.
16. Edmonson J H, Ryan L M, Blum R H, et al. (1993). Randomised comparison of doxorubicin alone versus ifosfamide + doxorubicin or mitomycin, doxorubicin, and cisplatin asainst advanced soft tissue sarcomas. J Clin Oncol II: 1269-75.
17. Eggermont A M, Lienard D, Schraffordt K H, et al. (1992). Limb salvage by high dose tumor necrosis factor-alpha, gamma-interferon and melphalan isolated limb perfusion in patients with unresectable soft tissue sarcomas. Proc ASCO II: 412Abs 1444.
18. Eilber F R, Eckardt J J, Rosen G, et al. (1993). Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft tissue sarcomas of the extremity. Surg Oncol Clin (North Am) 2: 611.
19. Eilber F R, Giuliano A E, Huth J F, et al. (I988). A randomised prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity softtissue sarcoma. Am J Clin Oncol 11 ( 1 ): 39-45.
20. Elias A D, Ayash L J, Eder J P et al. (1991). A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 9: 320-27.
21. Elias A, Ryan L, Sulkes A et al. ( 1989).Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208.
22. Gherlinzoni F, Picca P, Bacci G, et al. (1993). Late results of a randomised trial for the treatment of soft tissue sarcomas of the extremities in adult patients. Proc ASCO 12: Abs 1633.
23. Hawkins M J (1993). Investigational agents. In: Cancer: Principles and Practice of Oncology (Ed. DeVita V T, Hellman S, Rosenberg S A). P.A. Lippincott Philadelphia 4: 349-58.
24. Kessinger A, Petersen K, Bishop M, et al. (1994). High dose therapy (HDT) with autologous hematopoietic stem cell rescue (HSCR) for patients with metastatic soft tissue sarcoma. Proc ASCO : 13: Abs 1674.
25. Martini N, McCormack P M (1988). Pulmonary resection in sarcoma metastases. In: Recent Concepts in Sarcoma Treatment (Ed. Ryan J R, Baker L O). Dordrecht, Kluwer Academic, pp 197-200.
26. Omura G A, Major F J, Blessing J A, et al. (1983). A randomised study of Adriamycin with and without dimethy l trazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52: 626-32.
27. Pezzi C, Pollock R, Evans H, et al. (I990). Preoperative chemotherapy for soft tissue sarcomas of the extremity. Ann Surg 211: 476-81.
28. Priebat D, Mulawar M, Markman Y, et al. (1994). Clinical outcome of neoadjuvant intra-arterial (IA) cis-platinum and continuous (IV) infusion Adriamycin for large high grade unresectable or borderline soft tissue sarcoma of the extremity. Proc Am Soc Clin Oncol 3: 473.
29. Ravaud A, Bui N, Coindre J, et ai. ( 1990). Adjuvant Chemotherapy with cyvadic in high risk soft tissue sarcoma: a randomised prospective trial. In: Adjuvant Therapy of Cancer VI, (Ed. Salmon S E). W.B. Saunders Co. Philadelphia, pp 556-66.
30. Roth J A (1988). Prognostic indicators for soft tissue sarcoma patients with pulmonary metastases. In: Recent Concepts In: Sarcoma Treatment (Ed. Ryan J R, Baker L O). Dordrecht Kluwer Academic, pp 191-96.
31. Saeter G, Talle K, Solheim O P (1995). Treatment of advanced high grade soft tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol36: 172-5.
32. Salem PA, Benjamin R S, Howard J, et al. (1991). A phase II trial of recombinant interferon alpha-2-b in the treatment of advanced metastatic and refractory sarcomas. Proc Am Acad Cancer Res : 32: 200.
33. Santoro A, Rouesse J, Steward W, et al. (1990). A randomised EORTC study in advanced soft tissue sarcomas (STS): ADM vs ADM + IFX vs CYVADIC. Proc Am Soc Clin Oncol 9: Abs 1196.
34. Schmidt R A, Conrad E U, Collins C, et al. (1993). Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 72 (9): 2593-2601.
35. Steward W P, Verweij J, Somers D, et al. (1993). Granulocyte-macrophage colony stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11: 15-21.
36. Sugarman J R, Bertino J, Woodruff D, et al. (1996). Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (STS). Proc ASCO 15: Abs 1699.
37. Sugarman S, Shorter J, Healey J, et al. (1996). Trial of high dose ifosfamide with edatrexate in patients with advanced sarcoma. Proc ASCO : 15: Abs 1691.
38. Tierney J F, Mosseri V, Stewart LA, et al. (1995). Adjuvant chemotherapy for soft-tissue sarcoma: review and metanalysis of the published results of randomised clinical trials. Br J Cancer 72: 469-75.
39. Van Glabbeke M, van Oosterom A T, Oosterhuis J W, et al. (1994). Prognostic factors in advanced soft tissue sarcoma (STS): An overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 5 (8): 171.
40. Van Hoesel Q G, Verweij J, Catimal G et al. (1994). Phase II study with Docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539-42.
41. Yang J C, Glatstein E J, Rosenberg S A, Antman K H. (1993). Sarcomas of soft tissue. In: Cancer: Principles and Practice of Oncology (Eds. DeVita V T, Hellman S, Rosenberg S A). P.A. Lippincott Philadelphia 4: 1436-88.
42. Zalupski M M, Baker L H (1995). Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin (Nth Am) 9 (4): 787-99.